The Gut-Brain Axis, BDNF, NMDA and CNS Disorders

Neurochemical Research

Volumn 41, Issue 11, 2016, Pages 2819-2835

  Maqsood, Raeesah ^a   Stone, Trevor W ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

BDNF; Kynurenine; Microbiota; NMDA; Schizophrenia

Indexed keywords

ANTIINFECTIVE AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PREBIOTIC AGENT; PROBIOTIC AGENT;

ANXIETY DISORDER; AUTISM; BRAIN; DEMENTIA; DEPRESSION; DIET SUPPLEMENTATION; EMBRYO DEVELOPMENT; GASTROINTESTINAL TRACT; HUMAN; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; METABOLISM; NERVE CELL PLASTICITY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CENTRAL NERVOUS SYSTEM DISEASES; GASTROINTESTINAL TRACT; HUMANS; NEURONAL PLASTICITY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84983462441     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-016-2039-1     Document Type: Review

References (206)

1. Rhee SH, Pothoulakis C, Mayer EA (2009) Principles and clinical implications of the brain–gut–enteric microbiota axis. Nat Rev Gastroenterol Hepatol 6:306–314
2. Lyte M (2013) Microbial endocrinology in the microbiome-gut-brain axis: how bacterial production and utilization of neurochemicals influence behavior. PLoS Pathog 9:AR1003726
3. Lyte M (2014) Microbial endocrinology: host-microbiota neuroendocrine interactions influencing brain and behavior. Gut Microbes 5:381–389
4. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu X, Kubo C, Koga Y (2004) Postnatal microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response in mice. J Physiol (Lond) 558:263–275
5. Bailey MT, Coe CL (1999) Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev Psychobiol 35:146–155
6. Francis D, Diorio J, Liu D, Meaney MJ (1999) Nongenomic transmission across generations of maternal behavior and stress responses in the rat. Science 286:1155–1158
7. Bercik P, Collins SM, Verdu EF (2012) Microbes and the gut–brain axis. Neurogastroenterol Motil 24:405–413
8. Sekirov I, Russell SL, Antunes LC, Finlay BB (2010) Gut microbiota in health and disease. Physiol Rev 90:859–904
9. Collins SM, Bercik P (2009) The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136:2003–2014
10. Santos J, Yang PC, Soderholm JD, Benjamin M, Perdue MH (2001) Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut 48:630–636
11. Soderholm JD, Perdue MH (2001) Stress and gastrointestinal tract. II. Stress and intestinal barrier function. Am J Physiol Gastrointest Liver Physiol 280:G7–G13
12. O’Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Dinan TG (2009) Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry 65:263–267
13. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M (2011) Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain Behav Immun 25:397–407
14. Turner JR (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9:799–809
15. Rodino-Janeiro BK, Alonso-Cotoner C, Pigrau M, Lobo B, Vicario M, Santos J (2015) Role of corticotrophin-releasing factor in gastrointestinal permeability. J Neurogastroenterol Motil 21:33–50
16. Steffen EK, Berg RD, Deitch EA (1988) Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis 157:1032–1038
17. Maes M, Kubera M, Leunis JC, Berk M (2012) Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. Affective Disord 141:55–62
18. O’Mahony SM, Hyland NP, Dinan TG, Cryan JF (2011) Maternal separation as a model of brain–gut axis dysfunction. Psychopharmacology (Berl) 214:71–88
19. Tannock GW, Savage DC (1974) Influences of dietary and environmental stress on microbial populations in the murine gastrointestinal tract. Infect Immun 9:591–598
20. Douglas-Escobar M, Elliott E, Neu J (2013) Effect of intestinal microbial ecology on the developing brain. J Amer Med Assoc (Paediat) 164:374–379
21. Zhou L, Foster JA (2015) Psychobiotics and the gut-brain axis: in the pursuit of happiness. Neuropsychiatr Dis Treat 11:715–723.
22. Desbonnet L, Clarke G, Traplin A, O’Sullivan O, Crispie F, Moloney RD, Cotter PD, Dinan TG, Cryan JF (2015) Gut microbiota depletion from early adolescence in mice: implications for brain and behaviour. Brain Behav Immun 48:165–173
23. Jorgensen BP, Hansen JT, Krych L, Larsen C, Klein AB, Nielsen DS, Josefsen K, Hansen AK, Sorensen DB (2014) A Possible link between food and mood: dietary impact on gut microbiota and behavior in BALB/c mice. PLoS One 9:AR e103398
24. Crumeyrolle-Arias M, Jaglin M, Bruneau A, Vancassel S, Cardona A, Dauge V, Naudon L, Rabot S (2014) Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats. Psychoneuroendocrinology 42:207–217
25. Heijtz RD, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S (2011) Normal gut microbiota modulates brain development and behaviour. Proc Nat Acad Sci USA 108:3047–3052
26. Hooper LV, Gordon JI (2001) Commensal host-bacterial relationships in the gut. Science 292:1115–1118
27. Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF (2013) The microbiome–gut–brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry 18:666–673
28. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA (2005) Diversity of the human intestinal microbial flora. Science 308:1635–1638
29. Stone TW (1993) The neuropharmacology of quinolinic acid and kynurenic acids. Pharmacol Revs 45:309–379
30. Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Disc 1:609–620
31. Stone TW, Darlington LG (2013) The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Brit J Pharmacol 169:1211–1227
32. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI (2005) Host–bacterial mutualism in the human intestine. Science 307:1915–1920
33. Nakazawa H, Enei H, Okumura S, Yamada H (1972) Bacterial synthes of l-tryptophan and its analogs 0.1. Synthesis of l-tryptophan from pyruvate, ammonia and indole. Agric Biol Chem 36:2523–2528
34. McEwen B (1999) Development of the cerebral cortex: XIII. Stress and brain development: II. J Amer Child Adolescent Psychiatry 38:101–103
35. McEwen BS (1992) Steroid-hormones-effect on brain-development and function. Hormone Res 37:1–10.
36. Juster R-P, Bizik G, Picard M, Arsenault-Lapierre G, Sindi S, Trepanier L, Marin MF, Wan N, Sekerovic Z, Lord C, Fiocco AJ, Plusquellec P, McEwen BS, Lupien SJ (2011) A transdisciplinary perspective of chronic stress in relation to psychopathology throughout life span development. Dev Psychopathol 23:725–776.
37. Hornig M, Weissenbock H, Horscroft N, Lipkin WI (1999) An infection-based model of neurodevelopmental damage. Proc Nat Acad Sci USA 96:12102–12107
38. Brown AS (2006) Prenatal infection as a risk factor in schizophrenia. Schizophren Bull 32:200–202
39. Brown AS (2011) The environment and susceptibility to schizophrenia. Prog Neurobiol 93:23–58
40. Meyer U, Feldon J (2010) Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 90:285–326
41. Borre YE, O’Keefe GW, Clarke G, Stanton C, Dinan TG, Cryan JF (2014) Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Molec Med 20:509–518
42. Romano-Keeler J, Weitkamp JH (2014) Maternal influences on fetal microbial colonization and immune development. Pediat Res 77:189–195
43. Grenham S, Clarke G, Cryan JF, Dinan TG (2011) Brain-gut-microbe communication in health and disease. Front Physiol 2:1–15
44. Ericsson AC, Akter S, Hanson MM, Busi SB, Parker TW, Schehr RJ, Hankins M, Ahner CE, Davis JW, Franklin CL, Amos-Landgraf JM, Bryda EC (2015) Differential susceptibility to colorectal cancer due to naturally occurring gut microbiota. Oncotarget 6:33689–33704
45. Biasucci G, Rubini M, Riboni S, Morelli L, Bessi E, Retetangos C (2010) Mode of delivery affects the bacterial community in the newborn gut. Early Human Dev 86:513–515
46. Wassenaar, Panigrahi P (2014) Is a foetus developing in a sterile environment? Letts Appl Microbiol 59:572–579
47. Satokari R, Gronroos T, Laitinen K, Salminen S, Isolauri E (2009) Bifidobacterium and Lactobacillus DNA in the human placenta. Letts Appl Microbiol 48:8–12
48. Dinan TG, Stilling RM, Stanton C, Cryan JF (2015) Collective unconscious: how gut microbes shape human behaviour. J Psychiatr Res 63:1–9
49. Collado MC, Rautava S, Aakko J, Isolauri E, Salminen S (2016) Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci Repts 6:art23129
50. Farshim P, Walton G, Chakrabarti B, Givens I, Saddy D, Kitchen I, Swann JR, Bailey A (2016) Maternal weaning modulates emotional behavior and regulates the gut-brain axis. Sci Repts 6:art21958
51. Paul HA, Bomhof MR, Vogel HJ, Reimer RA (2016) Diet-induced changes in maternal gut microbiota and metabolomic profiles influence programming of offspring obesity risk in rats. Sci Repts 6:art20683
52. Tochitani S, Ikeno T, Ito T, Sakurai A, Yamauchi T, Matsuzaki H (2016) Administration of non-absorbable antibiotics to pregnant mice to perturb the maternal gut microbiota is associated with alterations in offspring behaviour. PLoS One 11:ARe0138293
53. Goldsmith F, O’Sullivan A, Smilowitz JT, Freeman SL (2015) Lactation and intestinal microbiota: how early diet shapes the infant gut. J Mamm Gland Biol Neoplasia 20:149–158
54. Snyder MA, Gao WJ (2013) NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci 7:1–12
55. Wenzel A, Fritschy JM, Mohler H, Benke D (1997) NMDA receptor heterogeneity during postnatal development of the rat brain: Differential expression of the NR2A, NR2B, and NR2C subunit proteins. J Neurochem 68:469–478
56. Contestabile A (2000) Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Rev 32:476–509
57. Adesnik H, Li G, During MJ, Pleasure SJ, Nicoll RA (2008) NMDA receptors inhibit synapse unsilencing during brain development. Proc Nat Acad Sci USA 105:5597–5602
58. du Bois, Huang X-F (2007) Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Res Rev 53:260–270
59. Gulati AS, Shanahan MT, Arthur JC, Grossniklaus E, Furstenberg RJ, Kreuk L, Henning SJ, Jobin C, Sartor RB (2012) Mouse background strain profoundly influences Paneth cell function and intestinal microbial composition. PLoS One 7:ARe32403
60. Benson AK, Kelly SA, Legge R, Ma FR, Low SJ, Kim J, Zhang M, Oh PL, Nehrenberg D, Hua KJ, Kachman SD, Moriyama EN, Walter J, Peterson DA, Pomp D (2010) Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci USA 107:18933–18938
61. Esworthy RS, Smith DD, Chu FF (2010) A strong impact of genetic background on gut microflora in mice. Int J Inflamm 2010:986046. doi:10.4061/2010/986046
62. Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13:701–712
63. Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang XX, Malinowski P, Jackson W, Blennerhassett P, Neufeld KA, Lu J, Khan WI, Corthesy-Theulaz I, Cherbut C, Bergonzelli GE, Collins SM (2010) Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology 139:2102–2112
64. Lyte M, Li W, Opitz N, Gaykema R, Goehler LE (2006) Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia Citrobacter rodentium. Physiol Behav 89:350–357
65. Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, Harris HMB, Coakley M, Lakshminarayanan B, O’Sullivan O, Fitzgerald GF, Deane J, O’Connor M, Harnedy N, O’Connor K, O’Mahony D, van Sinderen D, Wallace M, Brennan L, Stanton C, Marchesi JR, Fitzgerald AP, Shanahan F, Hill C, Ross RP, O’Toole PW (2012) Gut microbiota composition correlates with diet and health in the elderly. Nature 488:178–184
66. Neufeld KM, Kang N, Bienenstock J, Foster JA (2010) Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil 23:255–264
67. de Theije CG, Wu JB, da Silva SL, Kamphuis PJ, Garssen J, Korte SM, Kraneveld AD (2011) Pathways underlying the gut–to–brain connection in autism spectrum disorders as future targets for disease management. Eur J Pharmacol 668:S70–S80
68. Parracho HM, Bingham MO, Gibson GR, McCartney AL (2005) Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol 54:987–991
69. MacFabe DF, Cain NE, Boon F, Ossenkopp KP, Cain DP (2011) Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: relevance to autism spectrum disorder. Behav Brain Res 217:47–54
70. Frohlich EE, Farzi A, Mayerhofer R, Reichmann F, Jacan A, Wagner B, Zinser E, Bordag N, Magnes C, Frohlich E, Kashofer K, Gorkiewicz G, Holzer P (2016) Cognitive impairment by antibiotic-induced gut dysbiosis: analysis of gut microbiota-brain communication. Brain Behav Immun 56:140–155
71. Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS (2003) Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther 10:61–67
72. Fuller-Thomson E, Lateef R, Sulman J (2015) Robust association between inflammatory bowel disease and generalized anxiety disorder: findings from a nationally representative Canadian study. Inflamm Bowel Dis 21:2341–2348
73. Mikocka-Walus A, Knowles SR, Keefer L, Graff L (2016) Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis 22:752–762
74. Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG (2010) Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience 170:1179–1188
75. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA (2011) Gastrointestinal flora and gastrointestinal status in children with autism—comparisons to typical children and correlation with autism severity. BMC Gastroenterol 11:1–13
76. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E, Summanin PH, Doreen G, Dixon D, Liu M, Molitoris DR, Green JA (2010) Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 16:444–453
77. Singh S, Kumar A, Agarwal S, Phadke SR, Jaiswal Y (2014) Genetic insight of schizophrenia: past and future perspectives. Gene 535:97–100
78. Nieto R, Kukuljan M, Silva H (2013) BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front Psychiatry 4:1–11
79. Dinan TG, Borre YE, Cryan JF (2014) Genomics of schizophrenia: time to consider the gut microbiome? Mol Psychiatry 19:1252–1257
80. Wei J, Hemmings GP (2005) Gene, gut and schizophrenia: the meeting point for the gene-environment interaction in developing schizophrenia. Med Hypoth 64:547–552
81. Nemani K, Ghomi RH, McCormick B, Fan X (2015) Schizophrenia and the gut-brain axis. Prog Neuro Psychopharmacol Biol Psychiatry 56:155–160
82. Wu JQ, Chen DC, Tan YL, Tan SP, Xiu MH, Wang ZR, De Yang F, Soares JC, Zhang XY (2016) Altered interleukin-18 levels are associated with cognitive impairment in chronic schizophrenia. J Psychiatr Res 76:9–15
83. Tan YL, Li YL, Tan SP, Wang ZR, Yang FD, Cao B, Zunta-Soares GB, Soares JC, Zhang XY (2015) Increased interleukin-2 serum levels were associated with psycho-pathological symptoms and cognitive deficits in treatment-resistant schizophrenia. Schizophrenia Res 169:16–21
84. Asevedo E, Rizzo LB, Gadelha A, Mansur RB, Ota VK, Berberian AA, Scarpato BS, Teixeira AL, Bressan RA, Brietzke E (2014) Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiol Behav 129:194–198
85. Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, Agartz I, Aukrust P, Andreassen OA (2013) Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophrenia Res 145:36–42
86. Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, Yoshida S, Arima K, Higuchi T, Amano N, Kunugi H (2013) Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 47:401–406
87. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OPH, Mors O, Mortensen PB (2009) Common variants conferring risk of schizophrenia. Nature 460:744–747
88. Pedrini M, Massuda R, Fries GR, de Bittencourt PMA, Schnorr CE, Moreira JCF, Teixeira AL, Lobato MIR, Walz JC, Belmonte-de-Abreu PS, Kauer-Sant’Anna M, Kapczinski F, Gama CS (2012) Similarities in oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 46:819–824
89. Song X, Fan X, Song X, Zhang J, Zhang W, Li X, Gao J, Harrington A, Ziedonis D, Lu L (2013) Elevated levels of adiponectin and other cytokines in drug naive first episode schizophrenia patients with normal weight. Schizophrenia Res 150:269–273
90. Fan X, Liu EY, Freudenreich O, Park JH, Liu D, Wang J, Yi Z, Goff D, Henderson DC (2010) Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophrenia Res 118:211–217
91. Davey KJ, O’Mahony SM, Schellekens H, O’Sullivan O, Bienenstock J, Cotter PD, Dinan TG, Cryan JF (2012) Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl) 221:155–169
92. Goto Y, Yang CR, Otani S (2010) Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders. Biolo Psychiatry 67:199–207
93. Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72:411–412
94. Perkins MN, Stone TW (1982) An iontophoretic investigation of the action of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247:184–187
95. Forrest CM, Khalil OS, Pisar M, Darlington LG, Stone TW (2013) Prenatal inhibition of the tryptophan-kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus. Brain Res 1504:1–15
96. Forrest CM, Khalil OS, Pisar M, McNair K, Kornisiuk E, Snitcofsky M, Gonzalez M, Jerusalinsky D, Darlington LG, Stone TW (2013) Changes in synaptic transmission and protein expression in the brains of adult offspring after prenatal inhibition of the kynurenine pathway. Neuroscience 254:241–259
97. Khalil OS, Pisar M, Forrest CM, Vincenten MCJ, Darlington LG, Stone TW (2014) Prenatal inhibition of the kynurenine pathway leads to structural changes in the hippocampus of adult rat offspring. Europ. J Neurosci 39:1558–1571
98. Pisar M, Forrest CM, Khalil OS, McNair K, Vincenten MCJ, Qasem S, Darlington LG, Stone TW (2014) Modified neocortical and cerebellar protein expression and morphology following prenatal inhibition of the kynurenine pathway. Brain Res 1576:1–17
99. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolites kynurenic acid inhibits α7-nicotinic receptor activity and increases non-α7 nicotinic receptor expression. J Neurosci 21:7463–7473
100. Mok MHS, Fricker AC, Weil A, Neurochem KJ (2009) Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology 57:242–249
101. Dobelis P, Staley KJ, Cooper DC (2012). Lack of modulation of nicotinic acetylcholine alpha-7 receptor currents by kynurenic acid in adult hippocampal interneurons. PLoS One 7:ARe41108
102. Arnaiz-Cot JJ, Gonzalez JC, Sobrado M, Baldelli P, Carbone E, Gandia L, Garcia AG, Hernandez-Guijo JM (2008) Allosteric modulation of alpha7nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmission. Eur J Neurosci 27:1097–1110
103. Cohen SM, Tsien RW, Goff DC, Halassa MM (2015) The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophren Res 167:98–107
104. Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CRED shut-off and cell death pathways. Nat Neurosci 5:405–414
105. Tsien JZ, Huerta PT, Tonegawa S (1996) The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 87:1327–1338
106. Moreau AW, Kullmann DM (2013) NMDA receptor-dependent function and plasticity in inhibitory circuits. Neuropharmacology 74:23–31
107. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48:627–640
108. Carlsson M, Carlsson A (1990) Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophren Bull 16:425–432
109. Gaspar PA, Bustamante ML, Silva H, Aboitiz F (2009) Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. J Neurochem 111:891–900
110. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with reduced nmda receptor expression display behaviors related to schizophrenia. Cell 98:427–436
111. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug-sernyl. AMA Arch Neurol Psychiatry 81:113–119
112. Jorgensen BP, Krych L, Penderson TB, Plath N, Redrobe JP, Hansen AK, Nielsen DS, Pendersen CS, Larsen C, Sørensen DB (2015) Investigating the long-term effect of subchronic phencyclidine-treatment on novel object recognition and the association between the gut microbiota and behavior in the animal model of schizophrenia. Physiol Behav 141:32–39
113. Shiraishi H, Ito M, Go TS, Mikawa H (1993) High-doses of penicillin decreases [H-3] flunitrazepam binding-sites in rat neuron primary culture. Brain and Dev 15:356–361
114. Feng HJ, Botzolakis EJ, Macdonald RL (2009) Context-dependent modulation of alpha beta gamma and alpha beta delta GABA(A) receptors by penicillin: implications for phasic and tonic inhibition. Neuropharmacology 56:161–173
115. Lindquist CEL, Dalziel JE, Cromer BA, Birnir B (2004) Penicillin blocks human alpha(1)beta(1) and alpha(1)beta(1)gamma(2S)GABA(A) channels that open spontaneously. Eur J Pharmacol 496:23–32
116. Macdonald RL, Barker JL (1977) Pentylenetetrazol and penicillin are selective antagonists of GABA-mediated post-synaptic inhibition in cultured mammalian neurons. Nature 267:720–721
117. Coyle JT (2012) NMDA Receptor and schizophrenia: a brief history. Schizophren Bull 38:920–926
118. Levin R, Dor-Abarbanel AE, Edelman S, Durrant AR, Hashimoto K, Javitt DC, Heresco-Levy U (2015) Behavioural and cognitive effects of the N-methyl-d-spartate receptor co-agonist d-serine in healthy humans: initial findings. J Psychiatr Res 61:188–195
119. Mothet J, Parent AT, Wolosker H, Brady RO, Linden DJ, Ferris CD, Rogawski MA, Snyder SH (2000). d-serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor. Proc Nat Acad Sci USA 97:4926–4931
120. Machado-Vieira R, Salvadore G, DiazGranados N, Zarate CA (2009) Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123:143–150
121. Coyle CM, Laws KR (2015) The use of ketamine as an antidepressant: a systematic review and meta-analysis. Human Psychopharmacol Clin Exp 30:152–163
122. Drewniany E, Han J, Hancock C, Jones RL, Lim J, Gorgani NN, Sperry JK, Yu HJ, Raffa RB (2015) Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression. J Clin Pharm Ther 40:125–130
123. Li CF, Chen XM, Chen SM, Mu RH, Liu BB, Luo L, Liu XL, Geng D, Liu Q, Yi LT (2016) Activation of hippocampal BDNF signaling is involved in the antidepressant-like effect of the NMDA receptor antagonist 7-chlorokynurenic acid. Brain Res 1630:73–82
124. Leal G, Afonso PM, Salazar IL, Duarte CB (2015) Regulation of hippocampal synaptic plasticity by BDNF. Brain Res 1621:82–101
125. Yang J, Siao CJ, Nagappan G, Marinic T, Jing D, McGrath K, Chen ZY, Mark W, Tessarollo L, Lee FS, Lu B, Hempstead L (2009) Neuronal release of pro-BDNF. Nat Neurosci 12:113–115
126. Matsumoto T, Rauskolb S, Polack M, Klose J, Kolbeck R, Korte M, Barde YA (2008) Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat Neurosci 11:131–133
127. Nagappan G, Zaitsev E, Senatorov VV, Yang J, Hempstead BL, Lu B (2009). Control of extracellular cleavage of ProBDNF by high frequency neuronal activity. Proc Nat Acad Sci USA 106:1262–1272
128. Patterson SL, Grover LM, Schwartzkroin PA, Bothwell M (1992) Neurotrophin expression in rat hippocampal slices: a stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs. Neuron 9:1081–1088
129. Aicardi G, Argilli E, Cappello S, Santi S, Riccio M, Thoenen H, Canossa M (2004) Induction of long-term potentiation and depression is reflected by corresponding changes in secretion of endogenous brain-derived neurotrophic factor. Proc Nat Acad Sci USA 101:15788–15792
130. Björkholm C, Monteggia LM (2016) BDNF—a key transducer of antidepressant effects. Neuropharmacology 102:72–79
131. Heldt SA, Stanek L, Chhatwal JP, Ressler KJ (2007) Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry 12:656–670
132. Adachi N, Numakawa T, Richards M, Nakajima S, Kunugi H (2014) New insight in expression, transport, and secretion of brain-derived neurotrophic factor: implications in brain-related diseases. World J Biol Chem 5:409–428
133. Chao MV (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4:299–309
134. Park H, Poo M (2013) Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 14:7–23
135. Gratacos M, Gonzalez JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X (2007) Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 61:911–922
136. Linnarsson S, Björklund A, Ernfors P (1997) Learning deficit in BDNF mutant mice. Eur J Neurosci 9:2581–2587
137. Ernfors P, Kucera J, Lee K, Loring J, Jaenisch R (1995) Studies on the physiological role of brain-derived neurotrophic factor and neurotrophin-3 in knockout mice. Int J Dev Biol 39:799–807
138. 67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatr Neurosci 36:195–203
139. Messias E, Chen CY, Eaton WW (2007) Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin N Am 30:323–338
140. McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67–76
141. Neufeld KM, Kang N, Bienenstock J, Foster JA (2011) Reduced anxiety-like behaviour and central neurochemical change in germ-free mice. Neurogastroenterol Motil 23:255–265
142. O’Sullivan E, Barrett E, Grenham S, Fitzgerald P, Stanton C, Ross RP, Quigley EMM, Cryan JF, Dinan TG (2011) BDNF expression in the hippocampus of maternally separated rats: does Bifidobacterium breve 6330 alter BDNF levels? Benef Microbes 2:199–207
143. Klug M, Hill RA, Choy KHC, Kyrios M, Hannan AJ, van den Buuse M (2012) Long-term behavioral and NMDA receptor effects of young-adult corticosterone treatment in BDNF heterozygous mice. Neurobiol Dis 46:722–731
144. Gareau MG, Wine E, Rodrigues DM, Cho JH, WharyMT, Philpott DJ, MacQueen G, Sherman PM (2011) Bacterial infection causes stress-induced memory dysfunction in mice. Gut 60:307–317
145. Shi L, Adams MM, Long A, Carter CC, Bennett C, Sonntag WE, Nicolle MM, Robbins M, D’Agostino R, Brunso-Bechtold JK (2006) Spatial learning and memory deficits after whole-brain irradiation are associated with changes in NMDA receptor subunits in the hippocampus. Radiation Res 166:892–899
146. Uekita T, Okaichi Y, Kaichi H (2006) Dissociation of the roles of NMDA receptor and hippocampus in rats’ spatial learning: the effects of environmental familiarity and task familiarity. Rev Neurosci 17:163–173
147. McDonald RJ, Hong NS, Craig LA, Holahan MR, Louis M, Muller RU (2005) NMDA-receptor blockade by CPP impairs post-training consolidation of a rapidly acquired spatial representation in rat hippocampus. Eur J Pharmacol 22:1201–1213
148. Daniel JM, Dohanich GP (2001) Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory. J Neurosci 21:6949–6956
149. Tao X, West AE, Chen WG, Corfas G, Greenberg ME (2002) A calcium-responsive transcription factor, Ca-rf that regulates neuronal activity-dependent expression of BDNF. Neuron 3:383–395
150. Suen PC, Wu K, Levine ES, Mount HTJ, Xu JL, Lin SY, Black IB (1997) Brain-derived neurotrophic factor rapidly enhances phosphorylation of the postsynaptic N-methyl-d-aspartate receptor subunit 1. Proc Nat Acad Sci USA 94:8191–8195
151. Caldeira MV, Melo CV, Pereira DB, Carvalho RF, Carvalho AS, Duarte CB (2007) BDNF regulates the expression and traffic of NMDA receptors in cultured hippocampal neurons. Mol Cell Neurosci 35:208–219
152. Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P, Thome J (2001) Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophren Res 52:79–86
153. Hashimoto K, Koizumi H, Nakazato M, Shimizu E, Iyo M (2005) Role of brain-derived neurotrophic factor in eating disorders: recent findings and its pathophysiological implications. Progr Neuropsychopharmacol Biol Psychiatry 29:499–504
154. Weickert CS, Hyde, Lipska BK, Herman MM, Weinberger DR, Kleinman JE (2003) Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 8:592–610
155. Lau D, Bengtson CP, Buchthal B, Bading H (2015) BDNF reduces toxic extrasynaptic NMDA receptor signaling via synaptic NMDA receptors and nuclear-calcium-induced transcription of inhba/Activin A. Cell Rep 12:1353–1366
156. Martire A, Pepponi R, Domenici MR, Ferrante A, Chiodi V, Popoli P (2013) BDNF prevents NMDA-induced toxicity in models of Huntington’s disease: the effects are genotype specific and adenosine A2A receptor is involved. J Neurochem 125:225–235
157. Vasquez CE, Riener R, Reynolds E, Britton GB (2014) NMDA receptor dysregulation in chronic state: a possible mechanism underlying depression with BDNF downregulation. Neurochem Intern 79:88–97
158. Bach SA, de Siqueira LV, Muller AP, Oses JP, Quatrim A, Emanuelli T, Vinade L, Souza DO, Moreira JD (2014) Dietary omega-3 deficiency reduces BDNF content and activation NMDA receptor and Fyn in dorsal hippocampus: Implications on persistence of long-term memory in rats. Nutr Neurosci 17:186–192
159. Mizuno M, Yamada K, He J, Nakajima A, Nabeshima T (2003) Involvement of BDNF receptor TrkB in spatial memory formation. Learn Mem 10:108–115
160. Park JK, Lee SJ, Kim TW (2014) Treadmill exercise enhances NMDA receptor expression in schizophrenia mice. J Exercise Rehab 10:15–21
161. Andoh A, Tsujikawa T, Fujiyama Y (2003). Role of dietary fiber and short-chain fatty acids in the colon. Curr Pharmaceut Design 9:347–358
162. Gundersen BB, Blendy JA (2009) Effects of the histone deacetylase inhibitor sodium butyrate in models of depression and anxiety. Neuropharmacology 57:67–74
163. Yamawaki Y, Fuchikami M, Morinobu S, Segawa M, Matsumoto T, Yamawaki S (2012) Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus. World J Biol Psychiatry 13:458–467
164. Valvassori SS, Varela RB, Arent CO, Dal-Pont GC, Bobsin TS, Budni J, Reus GZ, Quevedo J (2014) Sodium butyrate functions as an antidepressant and improves cognition with enhanced neurotrophic expression in models of maternal deprivation and chronic mild stress. Curr Neurovasc Res 11:359–366
165. Wei YB, Melas PA, Wegener G, Mathé AA, Lavebratt C (2015) Antidepressant-like effect of sodium butyrate is associated with an increase in TET1 and in 5-hydroxy-methylation levels in the bdnf gene. Intern J Neuropsychopharmacol 2015:1–10
166. Stilling RM, Dinan TG, Cryan JF (2014) Microbial genes, brain and behaviour—epigenetic regulation of the gut-brain axis. Genes Brain Behav 13:69–86
167. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF (2011) Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 108:16050–16055
168. Miller PE, Haberlen SA, Brown TT, Margolick JB, DiDonato JA, Hazen SL, Witt MD, Kingsley LA, Palella FJ, Budoff M, Jacobson LP, Post WS, Sears CL (2016) Intestinal microbiota-produced trimethylamine-n-oxide and its association with coronary stenosis and HIV Serostatus. J Acq Immun Def Synd 72:114–118
169. Wang ZN, Roberts AB, Buffa JA, Levison BS, Zhu WF, Org E, Gu XD, Huang Y, Zamanian-Daryoush M, Culley MK, DiDonato AJ, Fu XM, Hazen JE, Krajcik D, DiDonato JA, Lusis AJ, Hazen SL (2015) Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163:1585–1595
170. Kuka J, Liepinsh E, Makrecka-Kuka M, Liepins J, Cirule H, Gustina D, Loza E, Zharkova-Malkova O, Grinberga S, Pugovics O, Dambrova M (2014) Suppression of intestinal microbiota-dependent production of pro-atherogenic trimethylamine N-oxide by shifting l-carnitine microbial degradation. Life Sci 117:84–92
171. Williams BB, Van Benschoten AH, Cimermancic P, Donia MS, Zimmermann M, Taketani M, Ishihara A, Kashyap PC, Fraser JS, Fischbach MA (2014) Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 16:495–503
172. Kibe R, Kurihara S, Sakai Y, Suzuki H, Ooga T, Sawaki E, Muramatsu K, Nakamura A, Yamashita A, Kitada Y, Kakeyama M, Benno Y, Matsumoto M (2014) Upregulation of colonic luminal polyamines produced by intestinal microbiota delays senescence in mice. Sci Repts 4:AR4548
173. Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, Koga Y, Sudo N (2012) Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol 303:G1288–G1295
174. Reigstad CS, Salmonson CE, Rainey JF, Szurszewski JH, Linden DR, Sonnenburg JL, Farrugia G, Kashyap PC (2015) Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J 29:1395–1403
175. de Felipe FL, Rivas BD, Munoz R (2014) Bioactive compounds produced by gut microbial tannase: implications for colorectal cancer development. Front Microbiol 5:art684
176. Frankenfeld CL, Atkinson C, Wahala K, Lampe JW (2014) Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethyl-angolensin from the isoflavone daidzein. Eur J Clin Nutr 68:526–530
177. Garcia-Villalba R, Beltran D, Espin JC, Selma MV, Tomas-Barberan FA (2013) Time course production of urolithins from ellagic acid by human gut microbiota. J Agric Food Chem 61(S18):8797–8806
178. Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD, Naslain D, De Backer F, Neyrinck AM, Delzenne NM (2009) Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 90:1236–1243
179. Takagaki A, Otani S, Nanjo F (2011) Antioxidative activity of microbial metabolites of (-)-epigallocatechin gallate produced in rat intestines. Biosci Biotechnol Biochem 75:582–585
180. Yang CW, Zhu X, Liu N, Chen Y, Gan HX, Troy FA, Wang B (2014) Lactoferrin up-regulates intestinal gene expression of brain-derived neurotrophic factors BDNF, UCHL1 and alkaline phosphatase activity to alleviate early weaning diarrhea in postnatal piglets. J Nutr Biochem 25:834–842
181. Abt MC, Artis D (2009) The intestinal microbiota in health and disease: the influence of microbial products on immune cell homeostasis. Curr Opin Gastroenterol 25:496–502
182. Salazar N, Gueimonde M, de los Reyes-Gavilan CG, Ruas-Madiedo P (2016) Exopolysaccharides produced by lactic acid bacteria and bifidobacteria as fermentable substrates by the intestinal microbiota. Crit Rev Food Sci Nutr 56:1440–1453
183. Brown LCW, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M, Sonnenburg JL, Comstock LE, Bluestone JA, Fischbach MA (2013) Production of alpha-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol 11:ARe1001610
184. Liu XY, Yang G, Geng XR, Cao YJ, Li N, Ma L, Chen S, Yang PC, Liu ZG (2013) Microbial products induce claudin-2 to compromise gut epithelial barrier function. PLoS One 8:ARe68547
185. Sainsbury A, Shi YC, Zhang L, Aljanova A, Lin Z, Nguyen AD, Herzog H, Lin S (2010) Y4 receptors and pancreatic polypeptide regulate food intake via hypothalamic orexin and brain-derived neurotropic factor dependent pathways. Neuropeptides 44:261–268
186. Al-Qudah M, Alkahtani R, Akbarali HI, Murthy KS, Grider JR (2015) Stimulation of synthesis and release of brain-derived neurotropic factor from intestinal smooth muscle cells by substance P and pituitary adenylate cyclase-activating peptide. Neurogastroenterol Motil 27:1162–1174
187. Liang S, Wang T, Hu X, Luo J, Li W, Wu X, Duan Y, Jin F (2015) Administration of Lactobacillus Helveticus ns8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience 310:561–577
188. Savignac HM, Corona G, Mills H, Chen L, Spencer JPE, Tzortzis G, Burnet PWJ (2013) Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-d-aspartate receptor subunits and d-serine. Neurochem Int 63:756–764
189. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, Verdu EF, Collins SM (2011). The intestinal microbiota affect central levels of brain-derived neurotrophic factor and behaviour in mice. Gastroenterology 141:599–609
190. Yum SY, Caracci G, Hwang MY (2009) Schizophrenia and eating disorders. Psychiatr Clin N Am 32:809–819
191. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V (2013) The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res 47:197–207
192. Fawzi MH, Fawzi MM (2012) Disordered eating attitudes in Egyptian antipsychotic naive patients with schizophrenia. Comp Psychiatry 53:259–268
193. Simonelli-Munoz AJ, Fortea MI, Salorio P, Gallego-Gomez JI, Sanchez-Bautista S, Balanza S (2012) Dietary habits of patients with schizophrenia: a self-reported questionnaire survey. Intern J Mental Health Nursing 21(3SI):220–228
194. Amani R (2007) Is dietary pattern of schizophrenia patients different from healthy subjects? BMC Psychiatry 7:AR15
195. Stokes C, Peet M (2004) Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms. Nutr Neurosci 7:247–249
196. Peet M (2004) International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis. Brit J Psychiatry 184:404–408
197. Holm-Hansen S, Low JK, Zieba J, Gjedde A, Bergersen LH, Karl T (2016) Behavioural effects of high fat diet in a mutant mouse model for the schizophrenia risk gene neuregulin 1. Genes Brain Behav 15:295–304
198. Gama CS, Canever L, Panizzutti B, Gubert C, Stertz L, Massuda R, Pedrini M, de Lucena DF, Luca RD, Fraga DB, Heylmann AS, Deroza PF, Zugno AI (2012) Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia. Schizophren Res 141:162–167
199. Jeong JJ, Woo JY, Kim KA, Han M, Kim DH (2015) Lactobacillus pentosus var. plantarum C29 ameliorates age-dependent memory impairment in Fischer 344 rats. Lett Appl Microbiol 60:307–314
200. Distrutti E, O’Reilly JA, McDonald C, Cipriani S, Renga B, Lynch MA, Fiorucci S (2014) Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. PLoS One 9:ARe106503
201. Gomez-Pinilla F (2008) Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci 9:568–578
202. Tsuruga K, Sugawara N, Sato Y, Saito M, Furukori H, Nakagami T, Nakamura K, Takahashi I, Nakaji S, Yasui-Furukori N (2015) Dietary patterns and schizophrenia: a comparison with healthy controls. Neuropsychiatr Dis Treat 11:1115–1120
203. Yu YC, Wu SJ, Li JX, Wang RY, Xie XP, Yu XF, Pan JC, Xu Y, Zheng L (2015) The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signalling. Metab Brain Dis 30:47–55
204. Guimaraes LR, Jacka FN, Gama CS, Berk M, Leitao-Azevedo CL, de Abreu MGB, Lobato MI, Andreazza AC, Cereser KM, Kapczinski F, Belmonte-de-Abreu P (2008) Serum levels of brain-derived neurotrophic factor in schizophrenia on a hypocaloric diet. Progr Neuro Psychopharmacol Biol Psych 32:1595–1598
205. Darlington LG, Ramsey NW, Mansfield JR (1986) Placebo-controlled, blind-study of dietary manipulation therapy in rheumatoid arthritis. Lancet 1:236–238
206. Connor B, Sun Y, von Hieber D, Tang SK, Jones KS, Maucksch C (2016) AAV(1/2)-mediated BDNF gene therapy in a transgenic rat model of Huntington’s disease. Gene Ther 23:283–295